Last reviewed · How we verify
Iloprost (Ventavis)
Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation.
Iloprost is a prostacyclin analog that binds to prostacyclin receptors on vascular endothelial and smooth muscle cells, causing vasodilation and inhibiting platelet aggregation. Used for Pulmonary arterial hypertension (PAH), Raynaud's phenomenon secondary to systemic sclerosis.
At a glance
| Generic name | Iloprost (Ventavis) |
|---|---|
| Also known as | Ventavis |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Iloprost mimics the natural prostacyclin (PGI2), a potent vasodilator and antiplatelet agent. By activating prostacyclin receptors (IP receptors), it increases intracellular cAMP levels, leading to relaxation of vascular smooth muscle, improved blood flow, and reduced platelet activation. This mechanism is particularly beneficial in pulmonary hypertension where it reduces pulmonary vascular resistance and improves hemodynamics.
Approved indications
- Pulmonary arterial hypertension (PAH)
- Raynaud's phenomenon secondary to systemic sclerosis
Common side effects
- Flushing
- Headache
- Hypotension
- Jaw pain
- Cough
- Syncope
Key clinical trials
- Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease (PHASE3)
- Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? (NA)
- Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO) (PHASE4)
- Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
- Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD) (NA)
- Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iloprost (Ventavis) CI brief — competitive landscape report
- Iloprost (Ventavis) updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI